Published in Lab Business Week, September 25th, 2005
The size of the investment is not disclosed.
The proceeds from JJDC's investment combined with investments from current investors as well as revenues from collaborative agreements will be used to advance 7TM Pharma's development and discovery programs with a focus on metabolic disorders.
"We are very pleased to include JJDC as investor in 7TM Pharma," said Mette Kirstine Agger, CEO of 7TM Pharma. "We have a strong investor group that is supporting us continuously...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.